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Angiopoietin-2 (ANG2/ANGPT2) has recently emerged as a promising target for the inhibition of
tumor metastasis. In this issue of Cell Reports, Minami et al. show that the calcineurin-NFAT
pathway promotes pulmonary tumor metastasis by inducing ANG2 in the lung endothelium.In order to colonize distant organs and
form metastases, circulating cancer cells
need to overcome the physical barrier
represented by the continuous endo-
thelial cell (EC) layer of the blood vessels
in the target organ. This process, termed
‘‘extravasation,’’ may be facilitated by
factors—either secreted by the primary
tumor or induced locally at the meta-
static site—that enhance the perme-
ability of the blood vessels in the
target organ and favor the transmi-
gration of the cancer cells to the new
environment (Valastyan and Weinberg,
2011). In this issue of Cell Reports,
Minami et al. (2013) show that tumor-
derived vascular endothelial growth fac-
tor (VEGF) activates a calcineurin-NFAT
pathway that increases Ang2/Angpt2
transcription preferentially in the lung
ECs in order to facilitate the pulmonary
metastasis of cancer cells (Figure 1).
These findings uncover a mechanism
linking tumor-derived VEGF to ANG2-
induced metastasis.
ANG2 is a proangiogenic factor
secreted by activated ECs that binds
the TIE2 receptor in a cell-autonomous
fashion in order to destabilize the blood
vessel and sustain angiogenesis (Gerald
et al., 2013). Recently, ANG2 was shown
to also promote pulmonary metastasis
in mouse models of cancer (Mazzieri
et al., 2011). Although these prometa-
static effects may depend, at least in
part, on ANG2-induced loosening of EC
junctions and increased vascular perme-
ability (Holopainen et al., 2012), it is
currently unclear whether they are pri-
marily mediated by ANG2 secreted
remotely by the primary tumor or involveCthe local induction of ANG2 in the meta-
static niche.
The NFAT proteins are transcription
factors that regulate diverse cellular func-
tions. Upon the release of calcium from
intracellular compartments, calcineurin
dephosphorylates NFAT proteins and
triggers their translocation to the cell nu-
cleus. In ECs, VEGF signaling increases
intracellular calcium levels, thereby acti-
vating NFAT-mediated transcription of
target genes (Mancini and Toker, 2009).
Although it has long been known that
VEGF signaling activates Ang2 transcrip-
tion in ECs (Oh et al., 1999), the molecular
regulation of this response is currently
poorly understood.
Minami et al. (2013) have identified
NFAT binding sites in the Ang2 enhancer
and showed VEGF-induced activation of
a reporter construct containing these se-
quences. Consistent with a direct role of
NFAT in Ang2 activation, overexpressing
DSCR1—a negative regulator of NFAT
(Mancini and Toker, 2009)—decreased
Ang2 transcription in cultured lung ECs.
Furthermore, ANG2 messenger RNA and
protein levels were increased in the ECs
of lung tumor nodules growing in Dscr1
knockout mice, which have hyperactive
NFAT. The authors also show that the
inhibition of the calcineurin-NFAT-ANG2
pathway by either genetic overexpression
of DSCR1 in ECs or ANG neutralization
(using a soluble TIE2 receptor) decreased
the incidence of pulmonary metastases
derived from subcutaneously growing
mouse B16melanomas or Lewis lung car-
cinomas. Altogether, these data illustrate
the direct regulation of Ang2 transcription
by NFAT.ell Reports 4, August 29, 2013 ª2013 The AuthInterestingly, the authors also find
increased endothelial expression of
ANG2 in metastatic in comparison to
primary tumors both in mouse- and
patient-derived samples. Although this
observation merits further investiga-
tion, it suggests a prominent role for
ANG2 in metastasis-associated pro-
cesses. Notably, the specific blockade of
ANG2 in mouse tumor models apparently
achieves more dramatic antitumor effects
in secondary (metastatic) tumors than
primary tumors (Mazzieri et al., 2011). In
addition to enhancing cancer cell extra-
vasation via loosening EC junctions
(Holopainen et al., 2012), ANG2 may
promote subsequent vascularization of
micrometastases by acting as a classic
proangiogenic growth factor. Minami
et al. (2013) observed enhanced expres-
sion of VCAM-1 and E-selectin in the
lung endothelium of Dscr1 knockout
tumor-bearing mice, consistent with the
ability of ANG2 to upregulate adhesion
molecules in activated ECs (Fiedler et al.,
2006). By increasing vascular permeability
and EC adhesion molecules, ANG2 also
promotes the extravasation of a variety
of inflammatory cells (Scholz et al.,
2011), some of which can foster the
proinvasive functions of cancer cells.
Thus, NFAT-mediated ANG2 upregulation
in the lung endothelium may favor meta-
stasis by multiple mechanisms.
A provocative insight from the study is
the lung-specific role of the NFAT-ANG2
pathway during metastatic coloniza-
tion. Indeed, subcutaneous mouse mela-
nomas or Lewis lung carcinomas up-
regulated ANG2 expression selectively in
the lung among the organs analyzed.ors 621Open access under CC BY-NC-ND license.
Figure 1. VEGF-Induced Activation of the Calcineurin-NFAT Pathway Upregulates ANG2 in
Lung ECs and Promotes Metastasis
VEGFA binding to VEGFR2 induces an increase in intracellular calcium (Ca2+), which activates NFAT-
mediated Ang2 transcription in lung ECs. Secreted ANG2 facilitates metastatic colonization of the lung
parenchyma by circulating cancer cells. This process may depend on ANG2-mediated disruption of EC
junctions (VE-cadherin and TIE2 complexes with ANG1) and the upregulation of EC adhesion molecules
(e.g., VCAM1). Increased vascular permeability may also enhance myeloid cell extravasation. The left
portion of the figure is adapted, in part, from Mancini and Toker (2009). P, phosphorylation; blue squares,
ANG1; orange squares, ANG2; orange circles, VEGF.Remarkably, it was found that preferential
VEGF expression and activity in the lung
could represent a key determinant of this
organ-specific response. Indeed, VEGF
protein levels, as well as the phosphoryla-
tion of the VEGF receptor 2, were sub-
stantially higher in the lung than in other
organs harvested from tumor-bearing
mice. These intriguing observations may
help explain, at least in part, the preferen-
tial lung tropism of the tested tumor types.
In this regard, increasing evidence indi-
cates that specific organ microenviron-
ments can be more or less permissive to
colonization by distinct cancer cell types.
Organ-specific determinants of cancer
metastasis include cytokine networks
and inflammatory cell types that may
operate differentially in distinct organ
microenvironments (Valastyan and Wein-
berg, 2011). The study by Minami et al.
(2013) suggests a prominent role for the
VEGF-NFAT-ANG2 pathway in driving
the pulmonary metastasis of primary622 Cell Reports 4, August 29, 2013 ª2013 Ttumors and will prompt further studies
that investigate the clinical significance
of this phenomenon.
It is worth noting that a recent study
(Im et al., 2013) showed that, although
ANG2 promoted pulmonary metastasis
of mouse colon adenocarcinoma cells,
it limited their metastatic growth in
the liver (the main site of colon carci-
noma metastasis). Because organ-spe-
cificmetastases might respond differently
to VEGF-induced ANG2, caution should
be applied to the use of ANG2 inhibitors
for treating a broad spectrum of metasta-
tic tumors. Furthermore, it remains to be
seen whether additional tumor types that
metastasize to the lung (e.g., breast ade-
nocarcinomas) broadly use the VEGF-
NFAT-ANG2 pathway to establish pulmo-
nary metastasis.
The calcineurin-NFAT pathway plays
important functions in immunity (Mancini
and Toker, 2009). For example, it regulates
cytokine production by a variety of inflam-he Authors Open access under CC BY-NC-ND license.matory cells. The study by Minami et al.
(2013) largely employed Dscr1 knockout
mice, which have hyperactive NFAT in
most tissues. Although inflammatory cells
do not express ANG2, NFAT activation in
metastasis-associated inflammatory cells
might have enhanced their prometa-
static functions in an ANG2-independent
manner. Likewise, transgenic overexpres-
sion of Dscr1 under the control of the Tie2
promoter—a strategy employed to sup-
press NFAT activation specifically in
ECs—may have also affected NFAT
pathway activity in subsets of hematopoi-
etic cells, such as stem and progenitor
cells and macrophages, that also express
TIE2 (Mazzieri et al., 2011). Although
ANG2 blockade by a soluble TIE2 receptor
abrogated the effects of NFAT activation,
additional studies are required in order to
dissect the relative contribution of endo-
thelial and hematopoietic NFAT activation
to the observed phenotypes.
The long-term use of effective calci-
neurin-NFAT inhibitors (e.g., cyclo-
sporine-A) paradoxically increases can-
cer risk by broadly interfering with
immune cell function. Thus, targeting
downstream effectors of prometastatic
NFAT activation may represent a more
practicable therapeutic strategy. ANG2
levels are frequently increased in the
plasma of patients with cancer and often
correlate with a worse prognosis (Gerald
et al., 2013). By establishing a direct
role for the VEGF-NFAT-ANG2 pathway
in promoting pulmonary metastasis of
distinct tumor types, the work of Minami
et al. (2013) supports the clinical rationale
of combining VEGF and ANG2 blockade
for the treatment of cancer types that
are prone to metastasize to the lung.REFERENCES
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